» Articles » PMID: 37767082

Case Report: Buprenorphine-precipitated Fentanyl Withdrawal Treated with High-dose Buprenorphine

Overview
Journal F1000Res
Date 2023 Sep 28
PMID 37767082
Authors
Affiliations
Soon will be listed here.
Abstract

Buprenorphine, a partial agonist of the mu-opioid receptor, is an increasingly prescribed medication for maintenance treatment of opioid use disorder. When this medication is taken in the context of active opioid use, precipitated withdrawal can occur, leading to acute onset of opioid withdrawal symptoms. Fentanyl complicates use of buprenorphine, as it slowly releases from body stores and can lead to higher risk of precipitated withdrawal. Describe the successful management of buprenorphine precipitated opioid withdrawal from fentanyl with high doses of buprenorphine. We seek to highlight how no adverse effects occurred in this patient and illustrate his stable transition to outpatient treatment. We present the case of a patient with severe opioid use disorder who presented in moderately severe opioid withdrawal after taking non-prescribed buprenorphine-naloxone which precipitated opioid withdrawal from daily fentanyl use. He was treated with high doses of buprenorphine, 148 mg over the first 48 hours, averaging 63 mg per day over four days. The patient reported rapid improvement in withdrawal symptoms without noted side effects and was able to successfully taper to 16 mg twice daily by discharge. This case demonstrates the safety and effectiveness of buprenorphine at high doses for treatment of precipitated withdrawal. While other options include symptomatic withdrawal management, initiating methadone or less researched options like ketamine, utilizing buprenorphine can preserve or re-establish confidence in this life-saving medication. This case also increases the previously documented upper boundary on buprenorphine dosing for withdrawal and should provide additional confidence in its use.

Citing Articles

Managing Opioid Withdrawal Symptoms During the Fentanyl Crisis: A Review.

Weber A, Trebach J, Brenner M, Thomas M, Bormann N Subst Abuse Rehabil. 2024; 15:59-71.

PMID: 38623317 PMC: 11016949. DOI: 10.2147/SAR.S433358.


Case Report: Buprenorphine-precipitated fentanyl withdrawal treated with high-dose buprenorphine.

Bormann N, Gout A, Kijewski V, Lynch A F1000Res. 2023; 11:487.

PMID: 37767082 PMC: 10521070. DOI: 10.12688/f1000research.120821.2.

References
1.
Jutras-Aswad D, Widlitz M, Scimeca M . Treatment of buprenorphine precipitated withdrawal: a case report. Am J Addict. 2012; 21(5):492-3. DOI: 10.1111/j.1521-0391.2012.00262.x. View

2.
Wesson D, Ling W . The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003; 35(2):253-9. DOI: 10.1080/02791072.2003.10400007. View

3.
Armenian P, Vo K, Barr-Walker J, Lynch K . Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review. Neuropharmacology. 2017; 134(Pt A):121-132. DOI: 10.1016/j.neuropharm.2017.10.016. View

4.
Morgan J, Schackman B, Leff J, Linas B, Walley A . Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2017; 85:90-96. PMC: 5750108. DOI: 10.1016/j.jsat.2017.07.001. View

5.
Bormann N, Gout A, Kijewski V, Lynch A . Case Report: Buprenorphine-precipitated fentanyl withdrawal treated with high-dose buprenorphine. F1000Res. 2023; 11:487. PMC: 10521070. DOI: 10.12688/f1000research.120821.2. View